Company intelligence / Profile preview
Predictive Biotech
- Ownership
- Private
- Development stage
- Other
Overview
The company has faced FDA warnings regarding its CoreCyte product, which was marketed for COVID-19 without proper authorization. The FDA issued a warning letter in August 2020 stating that Predictive Biotech was marketing an unapproved biological product.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Human cell and tissue products
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Predictive Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Predictive Biotech.